Abstract
The discovery of a neuroprotective treatment is a high priority for research in Parkinsons disease. Substantial progress has been made towards this goal in recent years, but at the present there is still no treatment which can be said to have proven neuroprotective effects. There is no single unifying model to account for the disease; indeed it seems likely that the etiology is a convergence of several causes. This multiplicity may prove helpful, because mitigation of only one or a few of the factors may produce clinically important benefit. This review emphasizes the strategies for discovery of new treatments. Current approaches to the development of neuroprotective treatments can be broadly characterized into three groups: 1) approaches based on the existing understanding of the mechanism of cell injury and death in PD; 2) approaches based on clues from the emerging knowledge of genetics of PD; and 3) approaches based on clues from the epidemiology and role of environmental factors in the etiology of PD. Some specific compounds and approaches are discussed to illustrate these strategies.
Keywords: Neuroprotective, Parkinson, genetics
Current Neuropharmacology
Title: Neuroprotective Strategies for Parkinsons Disease
Volume: 2 Issue: 3
Author(s): Ippolita Cantuti-Castelvetri and David G. Standaert
Affiliation:
Keywords: Neuroprotective, Parkinson, genetics
Abstract: The discovery of a neuroprotective treatment is a high priority for research in Parkinsons disease. Substantial progress has been made towards this goal in recent years, but at the present there is still no treatment which can be said to have proven neuroprotective effects. There is no single unifying model to account for the disease; indeed it seems likely that the etiology is a convergence of several causes. This multiplicity may prove helpful, because mitigation of only one or a few of the factors may produce clinically important benefit. This review emphasizes the strategies for discovery of new treatments. Current approaches to the development of neuroprotective treatments can be broadly characterized into three groups: 1) approaches based on the existing understanding of the mechanism of cell injury and death in PD; 2) approaches based on clues from the emerging knowledge of genetics of PD; and 3) approaches based on clues from the epidemiology and role of environmental factors in the etiology of PD. Some specific compounds and approaches are discussed to illustrate these strategies.
Export Options
About this article
Cite this article as:
Cantuti-Castelvetri Ippolita and Standaert G. David, Neuroprotective Strategies for Parkinsons Disease, Current Neuropharmacology 2004; 2 (3) . https://dx.doi.org/10.2174/1570159043359585
DOI https://dx.doi.org/10.2174/1570159043359585 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Serum Biochemical Markers of Brain Injury
Mini-Reviews in Medicinal Chemistry Novel Multifunctional Anti-Alzheimer Drugs with Various CNS Neurotransmitter Targets and Neuroprotective Moieties
Current Alzheimer Research Sorting Mechanism of Peptide Hormones and Biogenesis Mechanism of Secretory Granules by Secretogranin III, a Cholesterol-Binding Protein, in Endocrine Cells
Current Diabetes Reviews Advances in Interleukin-12 Gene Therapy for Acquired Liver Diseases
Current Gene Therapy Loss in Toxic Function of Aggregates of α -Synuclein Mutants by a β-Synuclein Derived Peptide
Protein & Peptide Letters Novel Histone Deacetylase Inhibitors for the Treatment of Pediatric Brain Tumors
Central Nervous System Agents in Medicinal Chemistry Prospective Teratology of Retinoic Acid Metabolic Blocking Agents (RAMBAs) and Loss of CYP26 Activity
Current Pharmaceutical Design An Integrated Drug Development Approach Applying Topological Descriptors
Current Computer-Aided Drug Design Neuroprotection by Association of Palmitoylethanolamide with Luteolin in Experimental Alzheimer’s Disease Models: The Control of Neuroinflammation
CNS & Neurological Disorders - Drug Targets Mitochondrial Permeability Transition as Target of Anticancer Drugs
Current Pharmaceutical Design Recent Advances in Targeted Anti-Vasculature Therapy: The Neuroblastoma Model
Current Drug Targets Nanoparticles: A Neurotoxicological Perspective
CNS & Neurological Disorders - Drug Targets Immunotherapies for Parkinson’s Disease: Progression of Clinical Development
CNS & Neurological Disorders - Drug Targets <i>Rhizoma Coptidis</i> for Alzheimer’s Disease and Vascular Dementia: A Literature Review
Current Vascular Pharmacology Mitochondrial Biogenesis: A Therapeutic Target for Neurodevelopmental Disorders and Neurodegenerative Diseases
Current Pharmaceutical Design Multifunctional Role of Pacap-Like Peptides in Molluscs
Protein & Peptide Letters The Clinical Prognostic Value of LRG1 in Esophageal Squamous Cell Carcinoma
Current Cancer Drug Targets Malaria and artemisinin derivatives: an updated review
Mini-Reviews in Medicinal Chemistry Estrogens and Thyroid Hormones: Non-Genomic Effects are Coupled to Transcription
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Insights Into Effects of Ellagic Acid on the Nervous System: A Mini Review
Current Pharmaceutical Design